Medtronic (NYSE:MDT) said last week that a revised safety analysis of its In.Pact drug-coated balloon has been accepted by the Journal of the American College of Cardiology.
Last month, the medtech titan reported that a programming error inadvertently caused mortality data to be omitted from a statistical analysis involving the company’s paclitaxel-coated balloon.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic updates on corrected safety analysis for paclitaxel-coated balloon appeared first on MassDevice.